Multiple Myeloma Hub

Several ongoing trials are evaluating belantamab mafodotin across different treatment settings, strategies, and patient populations, as summarized in our latest visual abstract.

Explore the full visual abstract here: multiplemyelomahub.com/medical-inform…

#MultipleMyeloma #myeloma #mmsm #MedEd

Results of a post hoc competing-risk analysis evaluating the contribution of disease progression and NRM to OS with Tec-Dara in patients with #RRMM in the MajesTEC-3 trial, were presented at #IMS2026.

Learn more: bit.ly/4iYenn5

#MedEd #myeloma #mmsm

Personalize your Multiple Myeloma Hub experience by creating a My Multiple Myeloma Hub account.

▪️ Bookmark articles
▪️ Select your areas of interest
▪️ View recommended content

 Create your account here: bit.ly/3U3kqgL

#mmsm #multiplemyeloma

🎧 In our latest podcast, Fredrik Schjesvold discusses the current positioning of belantamab mafodotin-based combinations in MM, including considerations around ocular toxicity and patient preferences when selecting treatment.

Listen here: bit.ly/4eFXuLt

#MultipleMyeloma #myeloma #mmsm #MedEd @MyelomaOslo

Intended for healthcare professionals. Independently supported by GSK. Funders are allowed no influence.

New publication 📝 Primary results from the phase III CERVINO study, presented at #IMS26, showed a higher ORR (74.0% vs 45.7%) and a 60% reduction in the risk of progression or death with etentamig vs SAT in patients with triple-class-exposed RRMM.

Learn more about RRMM: multiplemyelomahub.com/types/malignan…
#MultipleMyeloma #myeloma #mmsm #MedEd